A Study to Compare the Natural History of Ataxia Telangiectasia (AT) in Children to Healthy Comparators (INSPIRE AT)
INSPIRE AT: Longitudinal Study Comparing the Natural History of Ataxia Telangiectasia in Children to Healthy Comparators
The primary objective of this study is to assess the natural history of AT symptoms and disease progression over time in children aged 1 to 10 years old diagnosed with classic AT.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Insmed Medical Information
- Phone Number: 1-844-446-7633
- Email: medicalinformation@insmed.com
Study Locations
-
-
-
Nottingham, United Kingdom, NG7 2UH
- Recruiting
- GBR001
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- Not yet recruiting
- USA004
-
-
Maryland
-
Baltimore, Maryland, United States, 21287-0005
- Recruiting
- USA002
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- USA001
-
-
Texas
-
Houston, Texas, United States, 77030-3008
- Recruiting
- USA003
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Participants who meet all the inclusion criteria and none of the exclusion criteria will be eligible for inclusion in their respective cohort as appropriate.
Description
Inclusion Criteria for the AT Cohort:
- Diagnosis of classic AT based on investigator's assessment of clinical presentation and genotyping.
- If three years to 10 years (<11 years) old, the primary caregiver has self-reported to the site that the participant with AT can walk approximately 33 feet (10 meters) without support from a helper, and without the use of a walking aid.
- Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver informed consent form.
Inclusion Criteria for the Healthy Comparator Cohort:
- Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver consent form.
Exclusion Criteria for the AT Cohort:
- Participation in a clinical trial of a candidate therapeutic for AT, with last administration of a candidate therapeutic within 30 days or five half-lives (whichever is longer) preceding study baseline (start of data collection). For clarity, ongoing clinical trial participation that does not involve a therapeutic drug is acceptable. An exception to this exclusion is that up to approximately 20 participants receiving levacetylleucine (marketed as AQNEURSA®) in investigational trials, expanded access programs, or as a licensed drug are eligible.
- Previous treatment with a chemotherapeutic agent for cancer.
- Diagnosis of a condition other than AT that, in the opinion of the investigator, would compromise AT symptom measurement or current study participation.
Exclusion Criteria for the Healthy Comparator Cohort:
- Diagnosis of any form of AT.
- Previous treatment with a chemotherapeutic agent for cancer.
- Diagnosis of a condition that, in the opinion of the investigator, would compromise the measurement of movement by wearable devices to serve as healthy comparators to AT participants.
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_CONTROL
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
AT Cohort
Participants with confirmed AT at screening visit will be enrolled and followed for 24 months. |
|
Healthy Comparator Cohort
Participants without diagnosis of AT at screening visit will be enrolled and followed for 24 months. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AT Cohort: Change From Baseline in AT Neurological Examination Scale Toolkit (A-TNEST) Score
Time Frame: Baseline up to Month 24
|
Baseline up to Month 24
|
|
AT Cohort: Change From Baseline in International Cooperative Ataxia Rating Scale (ICARS) Score
Time Frame: Baseline up to Month 24
|
Baseline up to Month 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Height
Time Frame: Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Change From Baseline in Weight
Time Frame: Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Percentage of Participants Achieving Pre-defined Developmental Goals as Assessed by Denver Developmental Screening Test (DDST-II)
Time Frame: Up to Month 24
|
Up to Month 24
|
|
|
AT Cohort: Change From Baseline in Pediatric Quality of Life Inventory (Peds QL) Score Measured by the Pediatric Quality of Life Inventory
Time Frame: Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Change From Baseline in Motor Activity Assessed by Wearable Device
Time Frame: Baseline up to Month 24
|
A wearable accelerometer will capture participant's movements during their everyday activities at home. These data will be processed using specific algorithms to generate measurements that include total sedentary time and time spent in light, moderate and vigorous activity. |
Baseline up to Month 24
|
|
Change From Baseline in Arm Function Assessed by Hevelius Test
Time Frame: Baseline up to Month 24
|
Baseline up to Month 24
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Study Director, Insmed Incorporated
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Primary Immunodeficiency Diseases
- Neurologic Manifestations
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Genetic Diseases, Inborn
- Metabolic Diseases
- Immune System Diseases
- Immunologic Deficiency Syndromes
- Neurocutaneous Syndromes
- Dyskinesias
- DNA Repair-Deficiency Disorders
- Cerebellar Diseases
- Cerebellar Ataxia
- Spinocerebellar Ataxias
- Ataxia
- Telangiectasis
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Ataxia Telangiectasia
Other Study ID Numbers
Other Study ID Numbers
- INS NHS AT001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.